Document Detail

Response to budesonide among atopic and non-atopic infants/preschoolers with recurrent wheezing.
MedLine Citation:
PMID:  19875223     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The treatment in non-atopic young children with recurrent wheezing remains controversial. OBJECTIVE: The aim of the study was to compare the response of inhaled budesonide in atopic versus non-atopic infants/preschoolers with recurrent wheezing (more than three episodes in the last year or one episode per month in the last three months). METHODS: One hundred and seventy three infants/preschoolers (mean age 1.58+/-0.9 yrs) with recurrent wheezing without previous use of inhaled corticosteroids were enrolled and divided into two categories: atopics (eosinophils in peripheral blood > or =4%) and non-atopics (<4%). Both groups were treated with budesonide (200 mcg bid delivered by MDI and spacer) for three months. The primary outcome was the prevalence of wheezing exacerbation episodes at the end of the treatment. RESULTS: Thirty-seven out of 173 (21.4%) were atopics and they were significantly younger, more frequently with a father with asthma, maternal grandparents with asthma and rhinitis, paternal and maternal grandparents with eczema, and higher number of wheezing episodes in the last year than non-atopics. At the end of the study, among those with good compliance (>70% of the weekly doses), the proportion of wheezing episodes were similar among atopics and non-atopics (57.7% vs. 44.1%, p=0.25, respectively); the number of exacerbations requiring emergency department (ED) visits and hospital admission were also similar. CONCLUSION: Regular budesonide therapy may decrease the episodes of wheezing in infants/preschoolers with recurrent wheezing, independently of atopy.
L Campusano; M Pastenes; C Fontecilla; J Escalona; C Salazar; J A Castro-Rodriguez
Related Documents :
20409023 - The tennessee children's respiratory initiative: objectives, design and recruitment res...
18061423 - Long-term repeatability of exhaled breath condensate ph in asthma.
7661433 - Transient cortical blindness in an infant exposed to methamphetamine.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article     Date:  2009-10-28
Journal Detail:
Title:  Allergologia et immunopathologia     Volume:  38     ISSN:  0301-0546     ISO Abbreviation:  Allergol Immunopathol (Madr)     Publication Date:    2010 Jan-Feb
Date Detail:
Created Date:  2010-02-09     Completed Date:  2010-05-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370073     Medline TA:  Allergol Immunopathol (Madr)     Country:  Spain    
Other Details:
Languages:  eng     Pagination:  31-6     Citation Subset:  IM    
Copyright Information:
Copyright 2009 SEICAP. Published by Elsevier Espana. All rights reserved.
Department of Pediatrics, Universidad de Antofagasta, Antofagasta, Chile.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Cortex Hormones / therapeutic use
Asthma / complications,  drug therapy,  prevention & control
Bronchodilator Agents / pharmacology,  therapeutic use*
Budesonide / pharmacology,  therapeutic use*
Child, Preschool
Cough / epidemiology
Eosinophilia / etiology
Follow-Up Studies
Hospitalization / statistics & numerical data
Hypersensitivity, Immediate / blood,  complications,  diagnosis,  drug therapy*
Maternal Age
Prospective Studies
Respiratory Sounds / drug effects*
Socioeconomic Factors
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Bronchodilator Agents; 51333-22-3/Budesonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inflammation Markers in the Exhaled Air of Patients with Bronchiectasis Unassociated with Cystic Fib...
Next Document:  The connection between early life wheezing and subsequent asthma: The viral march.